Session Speakers:
Importance of Disulfide Bond re-arrangement in vitro and in vivo: Evidence and Approaches to Address It
Franta Hubálek, Novo Nordisk A/S
Development of a Rapid and Automated, Compliance Ready Workflow for Full Sequence Coverage of RNAi Therapeutics
Jennifer Nguyen, Alnylam Pharmaceuticals
Elucidation, Characterization and Monitoring of a Unique Tyrosine Sulfation Post-Translational Modification During Bispecific Antibody Process Development and Scaleup
David Mahon, Bristol-Myers Squibb Company